UBS Sticks to Its Hold Rating for Qiagen (QGEN)

UBS analyst Dan Leonard maintained a Hold rating on Qiagen (QGEN – Research Report) today and set a price target of €44.00. The company’s shares closed yesterday at $42.30.

Leonard covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Charles River Labs, and Qiagen. According to TipRanks, Leonard has an average return of 9.5% and a 57.39% success rate on recommended stocks.

In addition to UBS, Qiagen also received a Hold from Kepler Capital ‘s Maja Pataki in a report issued on April 15. However, on April 17, Bank of America Securities maintained a Buy rating on Qiagen (NYSE: QGEN).

QGEN market cap is currently $9.22B and has a P/E ratio of 27.30.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Qiagen (QGEN) Company Description:

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.